West Lafayette, Indiana, United States · On-site
Our Company Genomenon is an AI-driven genetic intelligence company on a mission to save and improve lives by making biomedical information actionable. Rare diseases and cancer affect more than 30 million people in the U.…
Skills: Organization, Time Management, Written Communication, Attention To Detail, Microsoft Excel
West Lafayette, Indiana, United States · Hybrid
Our Company Genomenon is an AI-driven genetic intelligence company on a mission to save and improve lives by making biomedical information actionable. Rare diseases and cancer affect more than 30 million people in the U.…
Skills: Organizational Skills, Time Management, Attention To Detail, Microsoft Excel, Independent Work
West Lafayette, Indiana, United States • On-site
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The specialist will monitor and respond to high-priority content requests using internal tools to collect and organize data. They are responsible for maintaining accurate records and collaborating with the broader team to achieve data acquisition goals.
Candidates must have access to a local university library and proficiency in Microsoft Excel. Strong organizational skills, professional communication, and the ability to work independently in a fast-paced environment are required.
Genomenon is an AI-driven genetic intelligence company on a mission to save and improve lives by making biomedical information actionable. Rare diseases and cancer affect more than 30 million people in the U.S. alone and hundreds of millions globally, yet most patients still face long diagnostic journeys and limited treatment options. Our goal is clear and ambitious: to deliver the information that shapes diagnosis and treatment for every rare disease and cancer patient.
We sit at the intersection of AI, genomics, and real world evidence. Genomenon transforms the global scientific literature into a literature derived, real world evidence (RWE) engine for precision medicine—combining large-scale AI with expert human curation to deliver clean, clinically actionable datasets. This approach fills critical gaps left by EHR and claims data, especially in rare disease and oncology, by showing how patients actually present, progress, and respond to therapy.
We turn vast, complex biomedical data—spanning genomics, clinical evidence, and scientific literature—into trusted intelligence that helps clinicians make better diagnostic and therapeutic decisions, and supports life sciences organizations in bringing better therapies to market faster.
Our work has real, measurable impact. Genomenon’s platforms and services are used by more than 250 clinical laboratories and pharma organizations worldwide to support diagnostic interpretation, variant curation, and evidence-based decision-making across the drug development lifecycle.
Each year, our technology helps inform care for tens of thousands of patients facing rare, complex, and time-sensitive conditions—reducing uncertainty and delivering answers when they matter most.
What makes Genomenon unique is our ability to support both clinical diagnostics and pharmaceutical innovation on a shared foundation of advanced AI, deep domain expertise, and rigorously curated data.
If you’re motivated by impact, energized by complexity, and excited to help shape the future of rare disease diagnosis and treatment, there’s no better place to do that work.
Genomenon team members are thoughtful, ambitious, and mission-driven professionals working across states and countries. Our team brings together scientists, clinicians, engineers, and commercial leaders who collaborate as equals and learn from one another every day.
We value curiosity, accountability, and people who thrive in fast-moving, high-impact environments.
We are guided by our core values:
Building a great company starts with building a diverse and inclusive team. We believe that people with different backgrounds, perspectives, and life experiences help us solve harder problems and build better solutions.
Genomenon is committed to inclusion across race, gender, age, religion, identity, disability, and background — in how we hire, how we work, and how we lead.
If you’re excited about the role but unsure whether you meet every qualification, we encourage you to apply. We’d rather review one more resume than miss the chance to meet someone exceptional.
Genomic intelligence for clinical diagnostics and precision medicine development
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is published. It is peer-reviewed. It is buried in 39 million biomedical articles, locked behind paywalls, hidden in tables, appendices, and supplemental datasets that most researchers and clinicians never find. Missing that evidence has consequences. Rare disease patients go undiagnosed. Cancer patients miss life-saving treatments built around variants their lab could not classify. Drug programs commit to development paths on incomplete data. Clinical trials miss eligible patients. Label expansions get left on the table. Genomenon was founded to close that gap. Fit-for-purpose AI-powered search indexes the 11.2 million full-text papers and 3.7 million supplemental tables and datasets standard tools miss. Eighty expert scientific curators review and validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. The difference is measured. Loxo@Lilly used Genomenon to expand the Retevmo label by 73 variants, broadening medullary thyroid cancer eligibility by 15%. Amicus added 1,300+ GLA variants for Fabry disease, with 534 deposited in ClinVar, expanding the Galafold label by 15 variants. In a published head-to-head, Genomenon identified 83% more PRKAG2 cardiomyopathy patients than ChatGPT plus OpenEvidence. More than 250 diagnostic labs and 75 biopharma programs rely on Genomenon today as the evidence layer behind precision medicine. We find the Real-World Evidence that changes rare disease and cancer patients’ lives.
Offices: 206 E Huron St, 114, Ann Arbor, Michigan 48104, US
Genomic intelligence for clinical diagnostics and precision medicine development
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is published. It is peer-reviewed. It is buried in 39 million biomedical articles, locked behind paywalls, hidden in tables, appendices, and supplemental datasets that most researchers and clinicians never find. Missing that evidence has consequences. Rare disease patients go undiagnosed. Cancer patients miss life-saving treatments built around variants their lab could not classify. Drug programs commit to development paths on incomplete data. Clinical trials miss eligible patients. Label expansions get left on the table. Genomenon was founded to close that gap. Fit-for-purpose AI-powered search indexes the 11.2 million full-text papers and 3.7 million supplemental tables and datasets standard tools miss. Eighty expert scientific curators review and validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. The difference is measured. Loxo@Lilly used Genomenon to expand the Retevmo label by 73 variants, broadening medullary thyroid cancer eligibility by 15%. Amicus added 1,300+ GLA variants for Fabry disease, with 534 deposited in ClinVar, expanding the Galafold label by 15 variants. In a published head-to-head, Genomenon identified 83% more PRKAG2 cardiomyopathy patients than ChatGPT plus OpenEvidence. More than 250 diagnostic labs and 75 biopharma programs rely on Genomenon today as the evidence layer behind precision medicine. We find the Real-World Evidence that changes rare disease and cancer patients’ lives.
Offices: 206 E Huron St, 114, Ann Arbor, Michigan 48104, US
